CARM
Carisma Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
0.18
PEG
0.00
P/B
-1.63
P/S
0.03
EV/EBITDA
-0.04
DCF Value
$-13.90
FCF Yield
-1580.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.1%
Operating Margin
20.6%
Net Margin
15.3%
ROE
-28.9%
ROA
122.7%
ROIC
-10330.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45.3M | $44.7M | $1.07 |
| Q2 2025 | $0.00 | $-9.8M | $-0.23 |
| Q1 2025 | $3.7M | $-9.3M | $-0.22 |
| Q4 2024 | $3.7M | $-17.6M | $-0.42 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.58
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.